Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Edward Shaw MD
To identify the overall (and relapse-free) survival of low-risk adult patients with supratentorial LGG (<40 years old who undergo gross total resection of a WHO grade II astrocytoma, oligodendroglioma, or mixed oligoastrocytoma) who are observed postoperatively.
Data for this trial is being collected via the NRG/RTOG Data Center.
Histologic proof of supratentorial WHO grade II astrocytoma, oligodendroglioma, or oligoastrocytoma confirmed by central pathology review prior to randomization.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.